According to Cytokinetics
's latest financial reports the company has $0.61 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.61 B | -21.44% |
2022-12-31 | $0.78 B | 65.93% |
2021-12-31 | $0.47 B | 1.63% |
2020-12-31 | $0.46 B | 106.15% |
2019-12-31 | $0.22 B | 13.27% |
2018-12-31 | $0.19 B | -26.09% |
2017-12-31 | $0.26 B | 72.09% |
2016-12-31 | $0.15 B | 40.21% |
2015-12-31 | $0.11 B | 33.9% |
2014-12-31 | $83.22 M | 7.08% |
2013-12-31 | $77.72 M | 5.04% |
2012-12-31 | $74 M | 50.95% |
2011-12-31 | $49.02 M | -31.57% |
2010-12-31 | $71.63 M | -37.56% |
2009-12-31 | $0.11 B | 101.75% |
2008-12-31 | $56.86 M | -52.51% |
2007-12-31 | $0.11 B | 9.31% |
2006-12-31 | $0.10 B | 43.73% |
2005-12-31 | $76.21 M | -27.9% |
2004-12-31 | $0.10 B | 200.38% |
2003-12-31 | $35.18 M | 31.23% |
2002-12-31 | $26.81 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Amgen AMGN | $10.94 B | 1,680.02% | ๐บ๐ธ USA |
Trevena TRVN | $34.95 M | -94.32% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $0.17 B | -72.30% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | $29.97 M | -95.12% | ๐บ๐ธ USA |
Array Technologies ARRY | $0.24 B | -59.49% | ๐บ๐ธ USA |